CD5CAR

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCD5CAR
Drug Alias Nameanti-CD5 CAR T-cell therapy (iCell Gene Therapeutics)CD5CAR
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionT-cell surface glycoprotein CD5 modulators
TargetsT-cell surface glycoprotein CD5
Therapy Area/IndicationsLymphoma, Non-HodgkinPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesiCell Gene Therapeutics LLC
China Registration ClassN/A

Develop Information

Active CompaniesiCell Gene Therapeutics LLC
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-HodgkinPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A